The Claim
In hemodialysis patients, vitamin K2 supplementation at 360 μg three times weekly for 18 months is not associated with an increased risk of adverse events, vascular access complications, or thrombosis.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients undergoing hemodialysis, taking vitamin K2 at 360 micrograms three times per week for 18 months does not increase the occurrence of adverse events, complications with vascular access, or blood clots.
See the scientific wording
In hemodialysis patients, vitamin K2 supplementation at 360 μg three times weekly for 18 months is not associated with increased risk of adverse events, vascular access complications, or thrombosis, despite concerns about its role in coagulation pathways.
Vitamin K2 activates a protein in blood vessel walls that stops calcium from building up in the wrong places; this process does not interfere with blood clotting or the function of dialysis access sites.
What the research says
1 studyThis study gave dialysis patients a daily vitamin K2 supplement for 18 months and found no increase in blood clots, heart problems, or issues with their dialysis tubes compared to those who didn’t take it.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.